2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Review slidesets and expert analyses of key data from the 2021 Clinical Oncology Virtual Scientific Meeting!

Hematologic Malignancies

Capsule Summary Slidesets

Results from this study suggest that the benefit–risk profile of ponatinib is optimized by starting at a dose of 45 mg/day and reducing the dose to 15 mg/day upon achieving response (≤1% BCR-ABL1IS).

Released: June 8, 2021

Brexucabtagene autoleucel produced durable, high rates of response in relapsed/refractory adult B-cell ALL with no unexpected safety signals.

Released: June 8, 2021

Enasidenib shows promising efficacy and tolerability in patients with high-risk IDH2-mutated MDS.

Released: June 7, 2021

Pooled analysis of clinical data suggests that venetoclax + azacitidine is both safe and efficacious in patients with secondary AML unfit for chemotherapy, including individuals with intermediate- or poor-risk cytogenetics.

Released: June 6, 2021

Early-stage results with ivosidenib and venetoclax with or without azacitidine suggest a high CRc with a tolerable safety profile in patients with IDH1-mutated myeloid malignancies

Released: June 11, 2021

Cytogenetic risk and MRD status identified as independent predictors of overall survival and relapse-free survival with oral azacytidine in this multivariate analysis.

Released: June 10, 2021

Among patients with CR/CRi on venetoclax + azacitidine, achieving MRD <10-3 was associated with longer duration of response, event-free survival, and overall survival, regardless of when MRD negativity was attained.

Released: June 7, 2021

In this head-to-head, randomized phase III trial, acalabrutinib proved to be noninferior to ibrutinib for PFS and demonstrated a more favorable safety profile, particularly regarding cardiovascular events.

Released: June 9, 2021

In patients with previously untreated CLL/SLL, fixed-duration treatment of ibrutinib plus venetoclax resulted in deep and durable responses with high rates of treatment completion.

Released: June 11, 2021

Addition of venetoclax to lenalidomide and rituximab in untreated MCL was well tolerated and showed early evidence of high response rates and undetectable MRD.

Released: June 16, 2021

Tisagenlecleucel, a CD19 targeted CAR T-cell therapy, demonstrated a high overall response rate with durable responses in adult patients with relapsed/refractory follicular lymphoma.

Released: June 11, 2021

After a median follow-up of approximately 4 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS and consistent safety profiles vs chemoimmunotherapy in adults with treatment-naive CLL.

Released: June 6, 2021

Based on longer follow-up data, epcoritamab continues to show a manageable safety profile, with low-grade CRS, along with high response rates at doses ranging from 0.75-60 mg across disease histologies.

Released: June 7, 2021

Results of this subgroup analysis show that KRd-ASCT, as compared with KRd12, and KR maintenance, as compared with R maintenance, prolonged PFS across all cytogenetic risk groups except patients with amp(1q).

Released: June 11, 2021

In patients with newly diagnosed MM, compared with observation, daratumumab maintenance significantly improved PFS and depth of response following induction/consolidation therapy.

Released: June 14, 2021

Subcutaneous elranatamab, a BCMA-/CD3-targeted bispecific antibody, had a manageable safety profile and encouraging activity in relapsed/refractory multiple myeloma as reported in the MagnetisMM-1 phase I trial.

Released: June 14, 2021

In patients with R/R MM, updated results with idecabtagene vicleucel suggest high response rates and durable responses, regardless of the number of prior therapies.

Released: June 7, 2021

Updated results from ICARIA-MM confirm significant PFS benefit and show improvement in time to next therapy with addition of isatuximab to pomalidomide/low-dose dexamethasone in relapsed/refractory myeloma.

Released: June 9, 2021

In heavily pretreated patients with relapsed/refractory multiple myeloma, PFS was comparable with ixazomib + dexamethasone and pomalidomide + dexamethasone as shown in a randomized phase II trial.

Released: June 9, 2021

Addition of isatuximab to carfilzomib/dexamethasone improved PFS in patients with difficult-to-treat R/R MM, including older patients, patients with MM refractory to previous therapy, and those with high-risk cytogenetics.

Released: June 8, 2021

Post-hoc analysis of the DREAMM-2 findings suggest that BCVA changes and patient-reported ocular symptoms are concordant with corneal exam findings after belantamab mafodotin treatment in the majority of cases.

Released: June 5, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue